Avalon team publishes study of the U.S. cost impact of procalcitonin testing in acute respiratory infections. The full article is accessible here. In the inpatient setting, the costs of procalcitonin guided compared to usual care for the one million member cohort was $ 2,083,545, compared to $ 2,780,322, resulting in net savings of nearly $ 700,000 to the IDN for 2014. In the ICU and outpatient settings, savings were $ 73,326 and $ 5,329,824, respectively, summing up to overall net savings of $6,099,927 for the cohort. Results were robust for all ARI diagnoses. For the whole US insured population, procalcitonin-guided care would result in $ 1.6 billion in savings annually.